Skip to content

Investors Overview

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated  low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies.  Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly”.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

 

 

Esperion Therapeutics (NASDAQ: ESPR) 3:59 PM ET on Jan 19, 2018
Last Price 77.20 Change +2.24(+2.988%) open 75.46 Day High 78.59 52-Week High 78.59
Volume 506,224 Previous Close 74.96 Day Low 74.78 52-Week Low 10.71

Press Releases

Load More